Research Reports

Summary

Adagene presented new Phase 1b/2 data at AACR 2026 showing muzastotug triple combinations achieved higher ORRs in HCC (66.7% vs 32.5%) and dose-dependent responses in MSS CRC versus controls.

Key takeaways

Muzastotug + atezolizumab + bevacizumab in HCC: 66.7% ORR (4/6 pts, mod RECIST) vs 32.5% (13/40) control; mPFS 8.2 vs 5.5 months.
HCC triplet well-tolerated: Grade 3+ TRAEs 50% (3/6) vs 45% (18/40) control; supports continuous high-dose dosing.
MSS CRC triplet (muzastotug + pembro + fruquintinib): 25% ORR at 10mg/kg (1/4), 40% at 15mg/kg (2/5); no DLTs or Grade 4/5 TRAEs.
Muzastotug has FDA Fast Track with KEYTRUDA for MSS mCRC without liver metastases.
Data highlight muzastotug's masking technology reducing toxicity for tumor-specific high-dose CTLA-4 efficacy.